Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Knowing me, knowing you: can a knowledge of risk factors for Alzheimer's disease prove useful in understanding the pathogenesis of Parkinson's disease?

Sutherland GT, Siebert GA, Kril JJ, Mellick GD.

J Alzheimers Dis. 2011;25(3):395-415. doi: 10.3233/JAD-2011-110026. Review.

PMID:
21441655
2.

Exploiting the potential of molecular profiling in Parkinson's disease: current practice and future probabilities.

Mellick GD, Silburn PA, Sutherland GT, Siebert GA.

Expert Rev Mol Diagn. 2010 Nov;10(8):1035-50. doi: 10.1586/erm.10.86. Review.

PMID:
21080820
3.

Effect of adjuvant-induced systemic inflammation in rats on hepatic disposition kinetics of taurocholate.

Roberts MS, Liu X, Zou Y, Siebert GA, Chang P, Whitehouse MW, Fletcher L, Crawford DH.

Am J Physiol Gastrointest Liver Physiol. 2011 Jan;300(1):G130-6. doi: 10.1152/ajpgi.00162.2010. Epub 2010 Oct 28.

4.

Haplotype analysis of the PARK 11 gene, GIGYF2, in sporadic Parkinson's disease.

Sutherland GT, Siebert GA, Newman JR, Silburn PA, Boyle RS, O'Sullivan JD, Mellick GD.

Mov Disord. 2009 Feb 15;24(3):449-52. doi: 10.1002/mds.22427.

PMID:
19117363
5.

Screening PARK genes for mutations in early-onset Parkinson's disease patients from Queensland, Australia.

Mellick GD, Siebert GA, Funayama M, Buchanan DD, Li Y, Imamichi Y, Yoshino H, Silburn PA, Hattori N.

Parkinsonism Relat Disord. 2009 Feb;15(2):105-9. doi: 10.1016/j.parkreldis.2007.11.016. Epub 2008 May 19.

PMID:
18486522
6.

Hepatic pharmacokinetics of propranolol in rats with adjuvant-induced systemic inflammation.

Hung DY, Siebert GA, Chang P, Whitehouse MW, Fletcher L, Crawford DH, Roberts MS.

Am J Physiol Gastrointest Liver Physiol. 2006 Feb;290(2):G343-51. Epub 2005 Sep 15.

7.

Therapeutic effects and possible mechanisms of a snake venom preparation in the fibrotic rat liver.

Chang P, Hung DY, Siebert GA, Bridle K, Roberts MS.

Dig Dis Sci. 2005 Apr;50(4):745-52.

PMID:
15844712
8.

Hepatic pharmacokinetics of taurocholate in the normal and cholestatic rat liver.

Hung DY, Siebert GA, Chang P, Roberts MS.

Br J Pharmacol. 2005 May;145(1):57-65.

9.

Reduced hepatic extraction of palmitate in steatosis correlated to lower level of liver fatty acid binding protein.

Hung DY, Siebert GA, Chang P, Burczynski FJ, Roberts MS.

Am J Physiol Gastrointest Liver Physiol. 2005 Jan;288(1):G93-100. Epub 2004 Sep 2.

10.

Disposition kinetics of propranolol isomers in the perfused rat liver.

Hung DY, Siebert GA, Chang P, Anissimov YG, Roberts MS.

J Pharmacol Exp Ther. 2004 Nov;311(2):822-9. Epub 2004 Jun 10.

PMID:
15192084
11.

A model to study intestinal and hepatic metabolism of propranolol in the dog.

Mills PC, Siebert GA, Roberts MS.

J Vet Pharmacol Ther. 2004 Feb;27(1):45-8.

PMID:
14995966
12.

Ion-trapping, microsomal binding, and unbound drug distribution in the hepatic retention of basic drugs.

Siebert GA, Hung DY, Chang P, Roberts MS.

J Pharmacol Exp Ther. 2004 Jan;308(1):228-35. Epub 2003 Oct 17.

PMID:
14566005
13.

Fatty acid binding protein is a major determinant of hepatic pharmacokinetics of palmitate and its metabolites.

Hung DY, Burczynski FJ, Chang P, Lewis A, Masci PP, Siebert GA, Anissimov YG, Roberts MS.

Am J Physiol Gastrointest Liver Physiol. 2003 Mar;284(3):G423-33. Epub 2002 Nov 20.

14.

Saturable dose-response relationships for melphalan in melanoma treatment by isolated limb infusion in the nude rat.

Roberts MS, Wu ZY, Siebert GA, Thompson JF, Smithers BM.

Melanoma Res. 2001 Dec;11(6):611-8.

PMID:
11725207
15.

Pharmacokinetics and pharmacodynamics of melphalan in isolated limb infusion for recurrent localized limb malignancy.

Roberts MS, Wu ZY, Siebert GA, Anissimov YG, Thompson JF, Smithers BM.

Melanoma Res. 2001 Aug;11(4):423-31.

PMID:
11479432
16.

Microdialysis and response during regional chemotherapy by isolated limb infusion of melphalan for limb malignancies.

Thompson JF, Siebert GA, Anissimov YG, Smithers BM, Doubrovsky A, Anderson CD, Roberts MS.

Br J Cancer. 2001 Jul 20;85(2):157-65.

17.
18.

Potencies of haloperidol metabolites as inhibitors of the human noradrenaline, dopamine and serotonin transporters in transfected COS-7 cells.

Bryan-Lluka LJ, Siebert GA, Pond SM.

Naunyn Schmiedebergs Arch Pharmacol. 1999 Aug;360(2):109-15.

PMID:
10494878

Supplemental Content

Loading ...
Support Center